Screening of Lung Cancer

Lung Cancer Screening

Apply to Clinical Trial

CONTACT
Screening+of+Colorectal+Cancer

The study is designed to prospectively collect peripheral blood samples, general medical information including demographic and medical history as well as cancer screening outcomes and any cancer diagnosis confirmed during your study participation.

This information will be used to further develop and evaluate content, methodology, specimen processing and quality control for test application in cancer screening.

Peripheral blood samples will be collected from individuals presenting for their routine colonoscopy-based colorectal cancer (CRC) screening.

The blood samples and subject data will be used for the development of cancer screening and detection products, including for lung cancer and CRC for which there are established screening methods, and select other cancer types with no widely adopted standard screening in asymptomatic individuals: including but not limited to ovarian, pancreatic, stomach, bladder, or liver cancer.

CLINICAL TRIAL LUNG CANCER

Patients must have DM, early satiety, nausea, and occasional vomiting.

Patients must meet the Inclusion / Exclusion criteria.

Must agree to follow the study requirements

Symptoms of the disease: early satiety, nausea, and occasional vomiting.

Inclusion:

  • Women and men 50-80 years at high risk for development of lung cancer and eligible for LDCT-based lung cancer screening as below:
  1. Current or previous cumulative cigarette smoking history of ≥ 20 pack years (packs per day multiplied by the number of years smoked)
  2. Former smokers must have quit smoking within the previous 15 years.
  • Willing and able to undergo LDCT screening within approximately 90 days from the date of enrollment blood draw
  • Women and men 45-85 years of age eligible for CRC screening.
  • Willing and able to undergo optical colonoscopy within approximately 90 days from the date of enrollment blood draw. Blood draw to occur 2 days before colonoscopy (i.e., bowel prep before colonoscopy)
  • Willing and able to provide peripheral blood samples.
  • Willing and able to provide written informed consent
  • Willing and able to participate in 1-3 years of follow- up

Exclusion:

  • Pre-existing or prior history of lung cancer
  • History of malignancy or has undergone, virtual (CT-based) colonoscopy, or flexible sigmoidoscopy within the past 5 years
  • Currently taking any anti-neoplastic treatment or disease modifying anti-rheumatic drugs (DMARDs)
  • Has undergone colonoscopy within the past 9 years
Share by: